Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland

11. Literatur 220
315. Perleth M. Bewertung von Leitlinien für die klinische Praxis. In: Perleth M., Antes G
(Hrsg) Evidenzbasierte Medizin – Wissenschaft im Praxisalltag. (1998) München, MMV
Medizin Verlag 1998;66–74.
316. Perry N, Broeders M, de Wolf C, Tornberg S. European Guidelines for Quality
Assurance in Mammography Screening. European Communities Publication,
Luxembourg 2001;3rd Edition.
317. Perry NM. Quality assurance in the diagnosis of breast disease (EUSOMA Working
Party). Eur J Cancer 2001;37:159–72.
318. Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement
regimes on mammographic breast parenchymal density. J Clin Oncol 1997;15:
3201–7.
319. Peto J. Cancer epidemiology in the last century and the next decade. Nature
2001;411:390–5.
320. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths
down 25% in year 2000 at age 20–69 years. Lancet 2000;355:1822.
321. Pfaff H, Klein J. Organisationsentwicklung im Gesundheitswesen. Med Klin
2002;97:309–15.
322. Philpotts LE, Lee CH, Horvath LJ, Lange RC, Carter D, Tocine I. Underestimation of
breast cancer with 11-gauge vacuum suction biopsy. AJR 2000;175:1047–50.
323. Philpotts LE, Shaheen N, Carter D. Comparison of rebiopsy rates after stereotactic core
needle biopsy of the breast with 11-gauge vacuum suction probe versus 14-gauge needle
and automatic gun. AJR 1999;172:683–7.
324. Pilote L, Tager IB. Outcomes research in the development and evaluation of practice
guidelines. BMC Health Serv Res 2002;2:7.
325. Pisano ED, Fajardo LL, Tsimikas J, et al. Rate of insufficient samples for fine-needle
aspiration for nonpalpable breast lesions in a multicenter clinical trial: The Radiologic
Diagnostic Oncology Group 5 study. Cancer 1998;82:678–88.
326. Pisano ED, Fajaro LL, Sneige N, et al. RDOG 5: Multicenter Study of the Diagnostic
Accuracy of Sonographically and Stereotactically – guided Fine Needle Aspiration for
Nonpalpable Lesion. Radiology 1999;213:289.
327. Poilpot S, Sebastien C, Buffet M, Akker M, Kujas A, Villet R. Stereotactic excisional
nonpalpable breast lesions using the advanced breast biopsy instrumentation. J
Gynecol Obstet Biol Reprod 2000;29:142–7.
328. Portincasa G, Lucci E, Navarra GG, Donato S, Parpanesi R, Garcea D. Initial
experience with breast biopsy utilizing the Advanced Breast Biopsy Instrumentation
(ABBI). J Surg Oncol 2000;74:201–3.
329. Potterton AJ, Peakman DH, Young IR. Ultrasound demonstration of small breast
cancers detected by mammographic screening. Clin.Radiol. 1994;49:808–13.
330. Prentice R, Thompson D, Clifford C, Gorbach S, Goldin B, Byar D. Dietary fat reduction
and plasma estradiol concentration in healthy postmenopausal women. J Natl
Cancer Inst 1990;82:129–34.
331. Prout MN. Breast cancer risk reduction: what do we know and where should we go?
Medscape Womens Health 2000;5.
332. Rand T, Heytmanek G, Seifert M, Wunderbaldinger P, Kreuzer S, Schneider B, et al.
Mammography in women undergoing hormone replacement therapy:possible effects
revealed at routine examination. Acta Radiol 1997;38:228–31.
333. Rebner M, Chesbrough R, Gregory N. Initial experience with the advanced breast
biopsy instrumentation device. AJR 1999;173:221–6.
334. Reinauer H. Entwicklung und Implementierung von ärztlichen Leitlinien im Gesundheitswesen.
Diabetes und Stoffwechsel 2001;10:213–8.
335. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive
score. (IRS) for immunohistochemical estrogen receptor detection (ER-ICA)
in breast cancer tissue]. Pathologe 1987;8:138–40.